FDA Approves Pfizer’s Abrysvo RSV Vaccine for Adults
Pfizer recently received approval from the U.S. Food and Drug Administration (FDA) for ABRYSVO®, its respiratory syncytial virus (RSV)...
Gilead Unveils Latest Liver Disease Research at AASLD 2024
Gilead Sciences is set to present over 40 research abstracts at The Liver Meeting® 2024, highlighting its commitment to...
New Study Links Antidepressant Use to Muscle Health and Cardiometabolic Risk
A recent study from AMRA Medical and the University of Oslo sheds light on the impact of antidepressants, specifically...
ArteraAI Prostate Test Now Accessible in CA
Artera, a company specializing in AI-powered cancer tests, has received a license from the California Department of Public Health,...
Vabysmo Improves Vision in Underrepresented DME Populations
A recent Phase IV clinical trial named ELEVATUM has shown promising results for Vabysmo, a medication used to treat...
Oncoprism® Earns Medicare Coverage: Predicting Immunotherapy Response
Cofactor Genomics, a clinical-stage company focused on RNA analysis for precision medicine, has received national coverage from Medicare contractor...
Vertex Unveils Suzетrigine as First-in-Class Pain Inhibitor at ASAnesthesia
Vertex Pharmaceuticals will unveil its pivotal Phase 3 data for suzetrigine, a potential non-opioid treatment for moderate-to-severe acute pain,...
Gilead and Merck Announce Phase 2 Islatravir and Lenacapavir Data
Gilead Sciences and Merck have announced positive results from a Phase 2 clinical trial investigating a novel combination therapy...
Clesrovimab Significantly Reduces RSV in Infants
Merck, known as MSD outside of the United States and Canada, announced positive results from their Phase 2b/3 clinical...
Actineer Begins Actinium-225 Production
Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has successfully produced Actinium-225 (Ac-225) by irradiating...